Unequal Premarket Treatment Sometimes Valid, CDRH Ombudsman Says
This article was originally published in The Gray Sheet
Executive Summary
Device manufacturers with similar products are not always treated equally in the premarket review process, but there is usually a legitimate reason for the discrepancies, CDRH Ombudsman Les Weinstein said
You may also be interested in...
FDA Dispute Panel Rebuffs Cardima’s Catheter A-Fib Claims
An FDA dispute resolution body all but halted Cardima's chances to turn around the fortunes of its Revelation Tx microcatheter NavAblator ablation system April 19, voting 5-0 not to recommend approval of the product
Increasing Number Of Appeals Add To Unresolved Issues For Ombudsman
CDRH's ombudsman says more manufacturer appeals of decisions made by the device center's evaluation office are causing longer resolution times for many complaints and disputes filed with the center
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.